Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 12/20 | 0.36 |
| ▸ | MMP2 | P08253 | 11/20 | 0.36 |
| ▸ | MMP1 | P03956 | 12/20 | 0.33 |
| ▸ | MMP9 | P14780 | 9/20 | 0.33 |
| ▸ | MMP8 | P22894 | 4/20 | 0.33 |
| ▸ | MMP13 | P45452 | 3/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.33 |
| ▸ | MMP7 | P09237 | 2/20 | 0.33 |
| ▸ | MMP14 | P50281 | 2/20 | 0.33 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | MMP20 | O60882 | 1/20 | 0.33 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
| ▸ | MMP10 | P09238 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | MMP15 | P51511 | 1/20 | 0.33 |
| ▸ | MMP16 | P51512 | 1/20 | 0.33 |
| ▸ | MMP25 | Q9NPA2 | 1/20 | 0.33 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8777490 | 1.00 | POLB (0.38) | POLBMMP3MMP2MMP1MMP9 | |
| SCHEMBL7513209 | 0.89 | MMP1 (0.44) | MMP3MMP2MMP1MMP9MMP8 | |
| SCHEMBL7410121 | 0.81 | MMP2 (0.47) | POLBMMP3MMP2MMP1 | |
| SCHEMBL9010568 | 0.80 | MMP1 (0.35) | MMP3MMP2MMP1MMP9MMP8 | |
| SCHEMBL8534029 | 0.80 | MMP3 (0.38) | POLBMMP3MMP2MMP1MMP9 | |
| SCHEMBL7370348 | 0.79 | MMP2 (0.46) | MMP3MMP2MMP1MMP9 | |
| SCHEMBL8026129 | 0.79 | MMP3 (0.40) | MMP3MMP2MMP1MMP9MMP8 | |
| SCHEMBL8422654 | 0.79 | MMP1 (0.34) | MMP3MMP2MMP1MMP9MMP8 | |
| SCHEMBL8197789 | 0.78 | MMP2 (0.39) | POLBMMP3MMP2MMP1MMP9 | |
| SCHEMBL7402956 | 0.78 | POLB (0.45) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0740653-B1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1999-08-04 | — | — | EP | claimed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| US-6133304-A | TREATING FIBROSIS, VENTRICULAR DILATION, AND/OR HEART FAILURE IN A MAMMAL BY ADMINISTERING AN ANTIFIBROTIC AMOUNT OF A MIXTURE OF AN ANGIOTENSIN-CONVERTING ENZYME(ACE) INHIBITOR AND AT LEAST ONE MATRIX METALLOPROTEINASE(MMP) INHIBITOR | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| EP-0740653-B1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1999-08-04 | — | — | EP | disclosed |
| EP-0740653-B1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1999-08-04 | — | — | EP | disclosed |
| US-5861436-A | INHIBITORS OF THE RELESE OF TUMOR NECROSIS FACTOR | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-01-19 | — | — | US | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| EP-0740653-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995019957-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | POLB 1752/4885MMP3 3/4885MMP2 19/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | POLB 1752/4885MMP3 3/4885MMP2 19/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | POLB 1752/4885MMP3 3/4885MMP2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.